Lupus Nephritis

Rituximab appears effective in lupus nephritis

Posted on

Off-label therapy with rituximab appears to be effective in patients with lupus nephritis (LN) after 6 months of treatment, according to a study.

In this retrospective cross-sectional study, data from 40 patients with LN who received Rituximab therapy were analyzed.

After 6 months, patients had significant improvements in renal function tests and significant decreases in the mean of the systemic lupus erythematosus (SLE) Activity Index 2000 with improvement in the histological degree of LN.

Improvement was common among patients with the following characteristics:
-Between the ages of 20 and 39 years
-Patients with disease duration <5 years
-Patients who received 4 doses
-Patients who received rituximab initial treatment

Abdelkarim Aloub KO, Eltahirm NIA, Elagib EM, et al. Efficacy and Safety of Rituximab Therapy for Lupus Nephritis Among SLE Female Patients; a Retrospective Hospital-Based Study. Open Access Rheumatol. 2022;14:301-308. doi: 10.2147/OARRR.S391091. PMID: 36536922; PMCID: PMC9758987.